Amyotrophic Lateral Sclerosis Therapeutics Market Size in the 7MM is expected to increase by 2034, estimated DelveInsight

DelveInsight's "Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ALS, historical and forecasted epidemiology as well as the ALS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Amyotrophic Lateral Sclerosis Market with DelveInsight's In-Depth Report @ Amyotrophic Lateral Sclerosis Market Size- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Amyotrophic Lateral Sclerosis Market Report
• Among the 7MM, the US accounted for the highest Amyotrophic Lateral Sclerosis prevalent cases in 2023, with around 26,000 cases; these cases are expected to increase during the forecast period.
• Amongst EU4 and the UK, the Amyotrophic Lateral Sclerosis diagnosed prevalent cases were highest in Germany, while the lowest number of cases was in Spain in 2023.
• The major sites of onset of Amyotrophic Lateral Sclerosis are the bulbar, and spinal, along with other uncertain regions. In 2023, the patients with the spinal as a site of onset accounted highest cases, i.e., 15,000, followed by the bulbar site of onset.
• According to the estimates, in Japan, it is observed that Amyotrophic Lateral Sclerosis was most prevalent in the 70-79 years age group, followed by 60-69 years, and 50-59 years.
• The leading Amyotrophic Lateral Sclerosis Companies such as Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
• Promising Amyotrophic Lateral Sclerosis Pipeline Therapies such as Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, and others.

Stay ahead in the Amyotrophic Lateral Sclerosis Therapeutics Market with DelveInsight's Strategic Report @ Amyotrophic Lateral Sclerosis Market Outlook- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Epidemiology Segmentation in the 7MM
• Amyotrophic Lateral Sclerosis Prevalence
• Amyotrophic Lateral Sclerosis Diagnosed Prevalence
• Amyotrophic Lateral Sclerosis Gender-specific Distribution
• Amyotrophic Lateral Sclerosis Mutation-specific Distribution
• Amyotrophic Lateral Sclerosis Type-specific Distribution
• Amyotrophic Lateral Sclerosis Distribution based on Site of onset
• Amyotrophic Lateral Sclerosis Age-specific Distribution

Navigate the complexities of the Amyotrophic Lateral Sclerosis Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Amyotrophic Lateral Sclerosis Market Forecast. Click here to get more insights @ Amyotrophic Lateral Sclerosis Prevalence- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Marketed Drugs
• RADICAVA/RADICUT (edaravone injection) and RADICAVA ORS: Mitsubishi Tanabe Pharma Corporation
RADICAVA is a product of Mitsubishi Tanabe Pharma that contains the active substance edaravone. It is a novel neuroprotective agent that slows down ALS progression. Notably, RADICAVA is the second drug to be approved for the treatment of ALS after more than two decades from the first US FDA approval of riluzole. Edaravone is available as a clear, colorless liquid provided as a sterile injection solution supplied for IV infusion; the substituted 2-pyrazolin-5-one class has the chemical name 3-methyl-1-phenyl-2-pyrazolin-5-one. The mechanism by which RADICAVA exerts its therapeutic effect in patients with ALS is unknown; however, it has anti-oxidant properties (Cruz, 2018b). Even after getting approval, the company is still conducting various clinical trial studies to better understand the drug's effects on a larger scale.

• RELYVRIO: Amylyx Pharmaceuticals
RELYVRIO (AMX0035) is an investigational neuroprotective therapy being developed to minimize neuronal death and dysfunction. In ALS and other neurodegenerative disorders, the drug targets endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways and blocks stress to maintain a balance between them. AMX0035 is a fixed-dose co formulation of two active compounds, namely, sodium phenylbutyrate (PB) and taurursodiol (tauroursodeoxycholic acid [TUDCA].

Amyotrophic Lateral Sclerosis Emerging Drugs
• Masitinib: AB Science
Masitinib (AB1010) is an orally administered tyrosine kinase inhibitor. It modulates mast cells and macrophages' activity - important cells for immunity - by targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Masitinib distinguishes itself from other ALS developmental drugs by exerting neuroprotection in both central and peripheral nervous systems. Based on its unique mechanism of action, masitinib can be developed in many conditions in oncology, inflammatory diseases, and certain diseases of the central nervous system. AB Science completed a Phase II/III trial and has attained positive results, followed by a green signal from the US FDA on the IND application. However, the drug is under investigation for a Phase III trial in patients with ALS.

• NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
MSC-NTF cells (NurOwn) are autologous bone marrow-derived mesenchymal stem cells (MSC) induced in culture to secrete high levels of neurotrophic factors (NTFs) that support neuronal growth and survival. Thus, MSC-NTF cells combine MSC's immunomodulatory therapeutic benefits with enhanced neurotrophic factor secretion.

Unlock insights into the Amyotrophic Lateral Sclerosis Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Amyotrophic Lateral Sclerosis Market Forecast. Click here @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Market Outlook
Scarcely any drugs have been approved by the FDA that can slow the course of the disease and improve the quality of life. Therefore, the management of ALS remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of gene therapy, cellular therapy, and neuroprotective agents. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates (measured by the ALS functional rating scale (ALSFRS-R).

Amyotrophic Lateral Sclerosis Drugs Market
The drug chapter segment of the ALS report encloses a detailed analysis of the marketed and late-stage (Phase III) pipeline drug. The marketed drugs segment encloses drugs such as RADICAVA (Mitsubishi Tanabe Pharma Corporation), RELYVRIO (Amylyx Pharmaceuticals), TIGLUTIK (ITF Pharma), and others. Furthermore, the current key players for emerging drugs and their respective drug candidates include AB Science (Masitinib), Brainstorm Cell Therapeutics (NurOwn), and others.

Gain a strategic edge in the Amyotrophic Lateral Sclerosis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Amyotrophic Lateral Sclerosis Market Forecast. Click here to lead in advancements @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Amyotrophic Lateral Sclerosis Market Research Report
• Coverage- 7MM
• Study Period- 2020-2034
• Amyotrophic Lateral Sclerosis Companies- Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
• Amyotrophic Lateral Sclerosis Pipeline Therapies- Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, and others.Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis Market Drivers and Barriers
• Amyotrophic Lateral Sclerosis Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Table of Content
1. Key Insights
2. Report Introduction
3. Amyotrophic Lateral Sclerosis Market Overview At A Glance
4. Amyotrophic Lateral Sclerosis Epidemiology And Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background And Overview
8. Amyotrophic Lateral Sclerosis Treatment And Management
9. Epidemiology And Patient Population Of The 7mm
10. Patient Journey
11. Amyotrophic Lateral Sclerosis Key Endpoints
12. Amyotrophic Lateral Sclerosis Marketed Drugs
13. Amyotrophic Lateral Sclerosis Emerging Drugs
14. Amyotrophic Lateral Sclerosis: 7mm Analysis
15. Unmet Needs
16. Amyotrophic Lateral Sclerosis SWOT Analysis
17. Amyotrophic Lateral Sclerosis KOL Views
18. Amyotrophic Lateral Sclerosis Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of the Top Selling Market Research Reports in 2025

Celiac Disease Market- https://www.delveinsight.com/report-store/celiac-disease-cd-market
Coronary Angioplasty Market- https://www.delveinsight.com/report-store/coronary-stents-market-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/overactive-bladder-market
Respiratory Syncytial Virus Market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Percutaneous Arterial Closure Device Market- https://www.delveinsight.com/report-store/vascular-closure-devices-market
Sglt2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Sealant Market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Radial Artery Compression Device Market- https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
Shingles Market - https://www.delveinsight.com/report-store/shingles-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
Catheter Stabilization Devices Market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
Orthopedic Splints Device Market- https://www.delveinsight.com/report-store/orthopedic-splints-market
Pediatric Neuroblastoma Market- https://www.delveinsight.com/report-store/neuroblastoma-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market-insight
Gene Therapy in CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/indwelling-catheters-market
CAR-T Pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
NK Cell Therapy Market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
Transcatheter Treatment Market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Phototherapies for Psoriasis Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Chronic Neuropathic Pain Market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Intraocular Lens Market - https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.